Exploring the Possible Beneficial Impact of Non-invasive and Invasive Neuromodulation on Freezing of Gait in Parkinson's Disease During Different Ambulatory Complexities: An Electrophysiological and fMRI Study

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20-90
SponsorChina Medical University Hospital

About this trial

Freezing of gait (FOG) stands out as a devastating symptom of Parkinson's disease (PD), where patients may become momentarily glued to the ground, rendering them incapable of walking efficiently. The pathogenesis of FOG remains uncertain but is likely attributed to functional perturbations in superficial cortical and deep locomotion regions. FOG tends to manifest more prominently during complex walking, such as turning, than during simple straight forward walking, and the reasons for this phenomenon remain unclear. Unfortunately, effective methods for overcoming this ambulatory issue has yet to be identified, and quantifying paroxysmal gait spells proves challenging with clinical rating alone; thus, a scientific tool is warranted. In this 3-year proposal, the investigators plan to address these challenges comprehensively.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Patients meet the diagnosis of PD based on the established consensus criteria

Age above 20 years old and below 90 years

For MRgFUS patients: a. At least one of the 3 cardinal symptoms (akinesia, tremor, rigidity) reaches an intensity of at least 2/4. b. Parkinsonian symptoms cannot be satisfactorily controlled by optimal pharmacological treatment including L-dopa and other antiparkinsonian drugs. c. stable medication for PD ≥ 30 days.

DBS patients must meet Taiwan Health Insurance criteria: PD duration exceeding 5 years, positive response to levodopa (≥33% UPDRS motor score improvement), and presence of motor complications (e.g., wearing off, on-off, levodopa-related dyskinesia, or medically intractable tremor).

Disqualifiers

Congestive heart failure (Functional III or above) or advanced cancer with distant metastasis.

PD at Hoehn and Yahr Stage 5.

DBS exclusion criteria: overt dementia or major depression.

Trial design

Design model

Crossover

Treatments tested in this trial

  • Transcranial direct current stimulation

    Device

    A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.

Treatment groups

20 Participants
are divided into 2 treatment groups
Group A: real tDCSExperimental treatment 1 intervention
Group B: sham tDCSSham comparator 1 intervention

Trial outcomes

Primary outcomes

1

Electroencephalogram recording before and after the tDCS session

Gait recording by 64 channels EEG device. Four different frequency bands ( theta, alpha, beta, and gamma) will be investigated. Variables in gait analysis: 1.Gait initiation, 2.Level walking, 3.Gait termination.

Time frame
baseline / 2 days, 2 and 4 weeks after the end of the tDCS session
2

Electromyography recording before and after the tDCS session

The 4 pairs of leg EMG recording during 50 meters walking. The EMG signals will be filtered with a band pass ranging from 0.05 to 70 Hz. Variables in gait analysis: 1.Gait initiation, 2.Level walking, 3.Gait termination.

Time frame
baseline / 2 days, 2 and 4 weeks after the end of the tDCS session
3

Functional magnetic resonance images examination before and after the tDCS session

fMRI scan will be performed on a 3.0T MR imager to detect the brain BOLD signal change in FOG. When fMRI was conducted, four different video tapes will be presented to the subjects#1.normal walking, 2.normal turning, 3.FOG during forward straight walking and 4.FOG during turning.

Time frame
baseline / 2 days after the end of the tDCS session
4

Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III before and after the tDCS session UPDRS contains four parts, the third part of which is reported in this outcome.

UPDRS contains four parts, the third part of which is reported in this outcome. Part III is clinician-scored monitored motor evaluation (14 questions, ranges from 0=normal to 4= Severe). The scoring of Part III varies between 0-56. The higher score indicates the worse motor function. Negative change from baseline values indicate improvement.

Time frame
baseline / 2 days, 2 and 4 weeks after the end of the tDCS session

Secondary outcomes

1

Change in New freezing of gait questionnaire (NFOG-Q) before and after the tDCS session

NFOG-Q contains three parts: in the first part, a video clip will be shown to the participants with PD and help to classify whether an individual is a freezer or non-freezer. The second and third part of the questionnaire is designed for freezers only. Par II (items 2-6, scores range between 0-19) assesses the severity of FOG according to the frequency and duration of the freezing episodes. Part III (items 7-9, scores range between 0-9) evaluates the impact of freezing on daily activities. The higher score indicates the worse freezing of gait. Negative change from baseline values indicate improvement.

Time frame
baseline / 2 days, 2 and 4 weeks after the end of the tDCS session
2

Change in Gait and Falls Questionnaire (GFQ) before and after the tDCS session

Gait and Falls Questionnaire assesses freezing of gait severity in patients with Parkinson's Disease (16 questions, ranges from 0=normal to 4= Severe). The scoring varies between 0-64. The higher score indicates the worse motor function. Negative change from baseline values indicate improvement.

Time frame
baseline / 2 days, 2 and 4 weeks after the end of the tDCS session

Other outcomes

1

Change in Tinetti's Mobility Index total score before and after the tDCS session

The Tinetti's Mobility Index contains two parts, Part I is Balance tests (9 questions, scores range between 0-16) and Part II is Gait tests (7 questions, scores range between 0-12). The scoring of this scale varies between 0 and 28 (\< 19 high fall risk, 19-24 medium fall risk, 25-28 low fall risk). Positive change from baseline values indicate improvement.

Time frame
baseline / 4 weeks after the end of the tDCS session
2

Change in Berg Balance Scale before and after the tDCS session

Berg Balance Scale is clinician-scored monitored motor evaluation (14 questions, ranges from 0=normal to 4= Severe). The scoring varies between 0-56. The higher score indicates the worse motor function. Negative change from baseline values indicate improvement.

Time frame
baseline / 4 weeks after the end of the tDCS session
3

Change inParkinson's Disease Questionnaire 39 (PDQ-39) before and after the tDCS session

PDQ-39 is composed of 39 questions, divided into 8 parts: mobility, activities of daily living (ADLs), emotional wellbeing, stigma, social support, cognition, communication and physical discomfort. It assesses how often people affected by Parkinson's experience difficulties across 8 dimensions of daily living. All questions range from 0 to 4 (0=never, 4=always). The scoring of this scale varies between 0-156. Negative change from baseline values indicate better quality of life rating.

Time frame
baseline / 4 weeks after the end of the tDCS session
4

Non-Motor Symptoms Questionnaire (NMSQ)

Non-Motor Symptoms Scale for Parkinson's Disease is composed of 30 questions, divided into 9 parts: Cardiovascular including falls, Sleep/fatigue, Mood/cognition, Perceptual problems/hallucinations, Attention/memory, Gastrointestinal tract, Urinary, Sexual function and Miscellaneous. The scoring method is frequency x severity (higher scores = more disability, lower scores = less disability). Negative change from baseline values indicate improvement.

Time frame
baseline / 4 weeks after the end of the tDCS session

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

China Medical University Hospital

Lead sponsor

Ministry of Science and Technology, Taiwan

Collaborator